about us

Meet the Team

Ashish Khanna

PRESIDENT & CHIEF EXECUTIVE OFFICER

Ashish Khanna is President & CEO of Allosite Therapeutics. He has over two decades of experience with life sciences companies and has built and managed successful teams across multiple entrepreneurial biotech ventures and led financings and transactions with an aggregate value of over $2.75 billion. He was formerly Chief Financial Officer and Chief Business Officer of Aptinyx, an R&D-stage company he co-founded to spin out early-stage technology from a predecessor company, Naurex. At Naurex, he was Vice President of Corporate Development and managed financing and transaction efforts, ultimately culminating in the company’s acquisition by Allergan. Previously, he was Director of Business Development at Vanda Pharmaceuticals. Earlier, he was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst & Young (later Capgemini). He current serves as a director on the boards of Longevity Biotech and the Illinois Biotechnology Innovation Organization. He received a BS in finance and BAS in systems engineering from the University of Pennsylvania, as well as an MBA from the Wharton School of the University of Pennsylvania.

Vineet Gupta, PhD

Founder and Chief Scientific Officer

Vineet Gupta, PhD is Founder and CSO of Allosite Therapeutics. Dr. Gupta is the Warmoth Professor in Hematology at the University of Texas Medical Branch John Sealy School of Medicine’s Department of Internal Medicine, Division of Nephrology. Dr. Gupta serves as Vice President for Innovation, Technology Development and Transfer. Prior to joining UTMB, he recently served as Professor and Vice Chair for Innovation in the Department of Internal Medicine at Rush University Medical Center in Chicago. He was the Charles Arthur Weaver Chair Professor of Cancer Research, Director of the Drug Discovery Center, and Director of the Section of Research in the Division of Hematology, Oncology, and Cell Therapies. Prior to joining Rush in 2012, he was Director of the Peggy and Harold Katz Drug Discovery Center at the University of Miami School of Medicine. Dr. Gupta is a Fellow of the National Academy of Inventors and focuses translational research on the discovery and development of novel integrin-targeted therapeutics.

Antonio Barbosa, PhD

Vice President, Research

Tony Barbosa, PhD is VP of Research at Allosite Therapeutics. Dr. Barbosa brings over 25 years working in drug discovery and has been recognized for three NIH SBIR grants and an Ed and Ethel Moore Alzheimer’s Disease Research Program grant. His expertise includes oncology and immunology & inflammation, targeting diseases like Alzheimer’s, cancer, and kidney disease. Previously, he directed chemistry at Adhaere Pharmaceuticals. Dr. Barbosa is also an Associate Professor at Ave Maria University, focusing on new Alzheimer’s treatments. He holds a Ph.D. in Organic Chemistry from the University of Rochester.

Patrick Flavin

Vice President, Corporate Development

Patrick Flavin is VP of Corporate Development at Allosite Therapeutics. He brings over 10 years of experience across biopharma corporate strategy, business development, and capital formation. Previously, he held corporate development positions at Autobahn Therapeutics and Aptinyx. He served as an Investment Associate with the University of Illinois early-stage venture capital fund and has led private and public financings and company formations with an aggregate value of over $500 million. He received his B.A. and MBA degrees from the University of Illinois Urbana-Champaign.

Darlah López-Rodriguez, PhD

Principal Scientist

Darlah Lopez-Rodriguez, PhD is Principal Scientist at Allosite Therapeutics. Dr. Lopez-Rodriguez brings over 10 years of experience in experimental biology and assay development in cell biology and immunology. She received her PhD and completed postdoctoral training at the University of Miami.

Santiago Balza Pineda, MSE

Associate Director, Operations

Santiago Balza Pineda is the Associate Director of Operations at Allosite Therapeutics. He brings more than five years of experience in immunology, protein engineering, and wet lab R&D and oversees the integration of research, development, and technology to advance antibody discovery and optimization. He leads the implementation of novel assay systems and machine learning capabilities that support the company’s therapeutic pipeline. He holds both a Bachelor’s and a Master’s of Science and Engineering in Biomedical Engineering from Johns Hopkins University.

Paola Gonzalez-Lerma, PhD

Staff Scientist

Paola Gonzalez-Lerma, PhD is Staff Scientist at Allosite Therapeutics. Dr. Gonzalez-Lerma has over 4 years of experience in experimental design and oncology andperforms small molecule characterization to advance our programs. She received her PhD in Biomedical Sciences from Florida Atlantic University.

Advisors

Julio Medina, PhD

Founder, CEO R2M Pharma

Contact

corporate@allositetx.com

1951 NW 7th Ave Ste 300
Miami, FL 33136, USA